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Abstract
Introduction
Little is known about the role of viral respiratory pathogens in the etiology, seasonality or
severity of severe acute respiratory infections (SARI) in the Eastern Mediterranean Region.
Methods
Sentinel surveillance for SARI was conducted from December 2007 through February 2014 at
20 hospitals in Egypt, Jordan, Oman, Qatar and Yemen. Nasopharyngeal and oropharyngeal
swabs were collected from hospitalized patients meeting SARI case definitions and were ana-
lyzed for infection with influenza, respiratory syncytial virus (RSV), adenovirus (AdV), human
metapneumovirus (hMPV) and human parainfluenza virus types 1–3 (hPIV1-3). We analyzed
surveillance data to calculate positivity rates for viral respiratory pathogens, describe the sea-
sonality of those pathogens and determine which pathogens were responsible for more
severe outcomes requiring ventilation and/or intensive care and/or resulting in death.
Results
At least one viral respiratory pathogen was detected in 8,753/28,508 (30.7%) samples
tested for at least one pathogen and 3,497/9,315 (37.5%) of samples tested for all patho-
gens–influenza in 3,345/28,438 (11.8%), RSV in 3,942/24,503 (16.1%), AdV in 923/9,402
(9.8%), hMPV in 617/9,384 (6.6%), hPIV1 in 159/9,402 (1.7%), hPIV2 in 85/9,402 (0.9%)
and hPIV3 in 365/9,402 (3.9%). Multiple pathogens were identified in 501/9,316 (5.4%) par-
ticipants tested for all pathogens. Monthly variation, indicating seasonal differences in levels
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of infection, was observed for all pathogens. Participants with hMPV infections and partici-
pants less than five years of age were significantly less likely than participants not infected
with hMPV and those older than five years of age, respectively, to experience a severe out-
come, while participants with a pre-existing chronic disease were at increased risk of a
severe outcome, compared to those with no reported pre-existing chronic disease.
Conclusions
Viral respiratory pathogens are common among SARI patients in the Eastern Mediterranean
Region. Ongoing surveillance is important to monitor changes in the etiology, seasonality
and severity of pathogens of interest.
Introduction
Acute respiratory infections (ARI) are the most common cause of morbidity worldwide [1, 2]
and the leading infectious cause of death for children under five years of age [3]. In 2010, ARI
were responsible for nearly 1.4 million deaths in children under five years of age, 18.3% of
total deaths in this age group [3].
Viral and bacterial etiologies of ARI cannot be distinguished clinically [4], so the microbio-
logical etiology of ARI is often unknown [5]. Data suggest the majority of ARI have a viral eti-
ology [6, 7], yet little attention was given to viral respiratory pathogens other than influenza
for many years [5] so the relative impact of these etiologies is poorly understood [6]. Yet the
role of these viruses in ARI morbidity and mortality is becoming increasingly apparent as diag-
nostics improve and become more widely available.
Surveillance for severe acute respiratory infections (SARI) offers an opportunity to examine
infections at the more serious end of the spectrum of ARI by focusing on hospitalized patients.
Investigating the etiology, seasonality and severity of these infections is key to understanding
disease that requires hospital admission and therefore is responsible for considerable morbid-
ity and mortality, as well as a substantial burden on both individual patients and the broader
healthcare system.
The epidemiology and impact of many viral respiratory pathogens have been described
in temperate climates [7–11], but published data from the Eastern Mediterranean Region
are limited. In 2007, the Eastern Mediterranean Acute Respiratory Infection Surveillance
(EMARIS) network was established and initiated sentinel-site surveillance for SARI through
collaboration by Ministries of Health in Egypt, Jordan and Oman in partnership with the U.
S. Centers for Disease Control and Prevention (CDC), U.S. Naval Medical Research Unit
No. 3 (NAMRU-3), and the World Health Organization (WHO). Over the next five years,
surveillance efforts expanded to include collaborations with Ministries of Health in Qatar
and Yemen.
We analyzed surveillance data from SARI patients enrolled at participating hospitals from
December 2007 through February 2014 to calculate proportions of positive samples for viral
respiratory pathogens, describe the seasonality of those pathogens, and determine which path-
ogens were responsible for more severe outcomes requiring ventilation or intensive care or
resulting in death. Specific pathogens of interest included influenza, respiratory syncytial virus
(RSV), adenovirus (AdV), human metapneumovirus (hMPV) and human parainfluenza virus
types 1–3 (hPIV1-3), as covered by the core respiratory diagnostic panel of CDC’s Interna-
tional Emerging Infections Program (IEIP) [12].
Viral SARI in EMR
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Materials and methods
Surveillance sites
The current analysis includes data from twenty hospitals conducting SARI surveillance in
Egypt, Jordan, Oman, Qatar and Yemen. Sentinel surveillance for SARI was established in
December 2007 at eight infectious disease hospitals in Egypt. One month later, surveillance
began at four general hospitals in Jordan and three general hospitals in Oman. In January
2010, surveillance activities in Egypt expanded to include Cairo University hospitals and Ain
Shams University hospitals. In August 2010, Qatar began SARI surveillance in the country’s
main hospital, and Yemen began SARI surveillance at two general hospitals in October 2010.
Participant enrollment
All sentinel hospitals adopted a standardized methodology for SARI surveillance. Hospital sur-
veillance teams screened all hospitalized patients with respiratory disease to assess whether
patients met a syndromic case definition for SARI. Due to an annual review by investigators
and updates to WHO guidelines, the case definition for SARI evolved over the study period
(S1 Table). From 2007 through 2009, the WHO SARI case definition (2006) was used [13].
During 2010–2011, the WHO SARI case definition was expanded to include cases of any age
greater than 31 days, cases that met the CDC IEIP pneumonia case definition [14] and any
case that a clinician suspected of SARI. In January 2012 the revised WHO SARI case definition
(2011) [15] was adopted, and cases with clinical suspicion of SARI continued to be enrolled
[16].
Eligible patients who met the SARI case definition were enrolled in the study, and either
written or oral informed consent (depending on country of enrollment) was obtained from
patients and/or their parents/guardians. A standardized questionnaire was used to collect data
on patient demographics, medical history, clinical signs and symptoms, treatment, clinical
course and outcome. Nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected and
combined in a single vial of viral transport media (VTM) from consenting patients.
Laboratory procedures
Samples were tested by real time reverse transcriptase polymerase chain reaction (rtRT-PCR)
to detect viral ribonucleic acid (RNA) for influenza virus (A or B) at the national central public
health laboratories, and aliquots of respiratory samples were then shipped to NAMRU-3 in
Cairo, Egypt. At NAMRU-3, total nucleic acid (TNA) was extracted from 200μl of each sample
using MagMAX™ Pathogen RNA/DNA Kit with the MagMAX™ Express-96 Deep Well Mag-
netic Particle Processor (Applied Biosystems1). For each sample, the human RNase P gene
was tested as an internal positive control to ensure proper sample collection and nucleic acid
extraction. TNA analyzed by polymerase chain reaction (PCR) to identify viral deoxyribonu-
cleic acid (DNA) for adenovirus (AdV) and rtRT-PCR to detect viral RNA for respiratory syn-
cytial virus (RSV), human metapneumnovirus (hMPV) and human parainfluenza virus types
1–3 (hPIV1-3) [17]. Primers and probes used were provided by the Gastroenteritis and Respi-
ratory Viruses Laboratory Branch of the National Center for Immunization and Respiratory
Diseases at the CDC.
Questionnaire data were entered into a Microsoft Access database by data managers
based either at the hospital or at the central Ministry of Health. Laboratory data were
recorded in a Microsoft Excel spreadsheet by laboratory technicians. Questionnaire and
laboratory data were linked using a unique study identification number assigned to each
participant at enrollment.
Viral SARI in EMR
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Data analysis
Data were analyzed using SAS software, version 9.3, of the SAS System for Windows (SAS
Institute Inc., Cary, North Carolina). Proportions of positive samples were calculated with
Clopper-Pearson confidence intervals [18]. Seasonality was examined by plotting the propor-
tion of positive samples by monthly intervals for each pathogen of interest. The chi-squared
test for heterogeneity was then used to assess the statistical significance of monthly variance in
the proportion of positive samples. Indicators of severe disease were assessed for each patho-
gen of interest using Mantel-Haenszel estimates to calculate odds ratios and confidence inter-
vals and the Mantel-Haenszel chi-squared test to assess statistical significance [19]. Logistic
regression was used to examine associations between viral respiratory pathogens and severe
outcomes, defined as illness requiring ventilation or intensive care or resulting in death, while
controlling for demographic and clinical characteristics. Only variables with statistically signif-
icant univariate association with severe outcomes were included in multivariate regression
analysis.
Ethics approval
Prior to study initiation, the study protocol was reviewed and approved by Institutional
Review Boards (IRBs) at CDC and NAMRU-3, as well as by host country Ministries of
Health, in compliance with all applicable federal U.S. regulations governing the protection
of human subjects and regulations of other participating institutions. IRBs and host country
regulators granted a waiver of documentation of informed consent and allowed a process of
verbal informed consent to be used due to the minimal risk faced by patients’ participation
in the study. The verbal consent process involved surveillance teams explaining the study to
patients, providing written study information to patients, allowing patients to consider par-
ticipation and ask questions. Consent (or lack thereof) for study participation and future
use of specimens was documented for all participants on the study consent form and the
study questionnaire.
Results
Etiology
Of 32,022 participants (14,291 < 5 years, 16,208 5 years, 1,523 age unknown) enrolled in
SARI surveillance between December 2007 and February 2014, 28,508 (89.0%, 12,612 < 5
years, 14,472 5 years, 1,424 age unknown) had an appropriate sample collected and tested
for at least one viral respiratory pathogen (influenza, RSV, AdV, hMPV, hPIV1, hPIV2 and/or
hPIV3). There were 9,315 (29.1%, 5,181< 5 years, 3,846 5 years, 288 age unknown) partici-
pants with samples for which testing for the full panel of viral respiratory pathogens was
performed.
Viral nucleic acid for at least one viral respiratory pathogen was detected in 8,753 (30.7%, 95%
CI 30.2–31.2%, 5,046< 5 years, 3,309 5 years, 398 age unknown) samples tested for at least one
pathogen and 3,497 (37.5%, 95% CI 36.6–38.5%, 2,822< 5 years, 614 5 years, 61 age unknown)
samples tested for the full panel of pathogens. Influenza was identified in 3,345/28,438 (11.8%,
95% CI 11.4–12.1%) participants, RSV in 3,942/24,503 (16.1%, 95% CI 15.6–16.6%), AdV in 923/
9,402 (9.8%, 95% CI 9.2–10.4%), hMPV in 617/9,384 (6.6%, 95% CI 6.1–7.1%), hPIV1 in 159/
9,402 (1.7%, 95% CI 1.4–2.0%), hPIV2 in 85/9,402 (0.9%, 95% CI 0.7–1.1%) and hPIV3 in 365/
9,402 (3.9%, 95% CI 3.5–4.3%) (Table 1).
RSV was the most common pathogen detected in each country except Egypt, where influ-
enza was the most common pathogen detected. The proportion of positive samples varied
Viral SARI in EMR
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across countries for all pathogens (p-values range from <0.01 to 0.03) except hPIV1 (p = 0.37)
and across years for all pathogens (p-values range from <0.01 to 0.01). hMPV was the only
pathogen for which different proportions of positive samples were found by sex (p = 0.04). All
pathogens were more common in children under the age of five years than in older partici-
pants (all p<0.01), except influenza, which was significantly more common in participants at
least five years of age (16.5% vs. 6.0%, p<0.01).
Multiple viral respiratory infections were identified in 501 (5.4%) samples tested for all
pathogens– 477 (5.1%) with two pathogens, 21 (0.2%) with three pathogens and three (<0.1%)
with four pathogens (Table 2). AdV was the most common virus present in co-infections
(n = 362), followed by RSV (n = 329), hMPV (n = 138), influenza (n = 121), hPIV3 (n = 97),
hPIV1 (n = 45) and hPIV2 (n = 24). The proportion of participants with co-infections varied
across countries and years and was significantly higher among children under the age of five
years than among older participants (8.1% vs. 2.0%, p<0.01) (Table 1).
Seasonality
Patterns of seasonality in the number of SARI cases tested for at least one viral respiratory
pathogen and the proportion of positive samples for each pathogen are shown in Fig 1.
The proportion of positive samples identified during each month is shown in Fig 2. The
proportion of samples positive for each pathogen of interest varied significantly by month
(influenza χ2 = 1098, p<0.01; RSV χ2 = 1263, p<0.01; AdV χ2 = 52, p<0.01; hMPV χ2 = 365,
p<0.01; hPIV1 χ2 = 90, p<0.01; hPIV2 χ2 = 76, p<0.01; hPIV3 χ2 = 158, p<0.01; all with 11
degrees of freedom).
Severity
No infections were independently associated with increased severity of illness, as indicated by
illness requiring ventilation and/or intensive care and/or resulting in death (Table 3). There was
strong evidence that participants with influenza, RSV, AdV or hMPV infection were less likely
Table 2. Coinfections by viral respiratory pathogen (n = 501). Includes 5 patients with influenza, RSV and AdV; 3 with influenza, RSV and hMPV; 3 with
RSV, AdV and hMPV; 3 with RSV, AdV and hPIV1; 2 with RSV, AdV and hPIV3; 2 with AdV, hMPV and hPIV3; 1 with influenza, AdV and hMPV; 1 with RSV,
AdV and hPIV2; 1 with RSV, hPIV1 and hPIV2; 1 with influenza, RSV, AdV and hMPV; 1 with RSV, AdV, hMPV and hPIV3; 1 with RSV, AdV, hPIV1 and
hPIV3.
Influenza RSV AdV hMPV hPIV1 hPIV2 hPIV3
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Influenza - 64 0.7 (0.5–
0.9)
30 0.3 (0.2–
0.5)
18 0.2 (0.1–
0.3)
1 0 (0.0–
0.1)
2 0 (0.0–
0.1)
6 0.1 (0.0–
0.1)
RSV 64 0.7 (0.5–
0.9)
- 181 1.9 (1.7–
2.2)
37 0.4 (0.3–
0.5)
13 0.1 (0.1–
0.2)
12 0.1 (0.1–
0.2)
22 0.2 (0.1–
0.4)
AdV 30 0.3 (0.2–
0.5)
181 1.9 (1.7–
2.2)
- 66 0.7 (0.5–
0.9)
24 0.3 (0.2–
0.4)
7 0.1 (0.0–
0.2)
54 0.6 (0.4–
0.8)
hMPV 18 0.2 (0.1–
0.3)
37 0.4 (0.3–
0.5)
66 0.7 (0.5–
0.9)
- 5 0.1 (0.0–
0.1)
0 0 (0.0–
0.0)
12 0.1 (0.1–
0.2)
hPIV1 1 0 (0.0–
0.1)
13 0.1 (0.1–
0.2)
24 0.3 (0.2–
0.4)
5 0.1 (0.0–
0.1)
- 1 0 (0.0–
0.1)
1 0 (0.0–
0.1)
hPIV2 2 0 (0.0–
0.1)
12 0.1 (0.1–
0.2)
7 0.1 (0.0–
0.2)
0 0 (0.0–
0.0)
1 0 (0.0–
0.1)
- 2 0 (0.0–
0.1)
hPIV3 6 0.1 (0.0–
0.1)
22 0.2 (0.1–
0.4)
54 0.6 (0.4–
0.8)
12 0.1 (0.1–
0.2)
1 0 (0.0–
0.1)
2 0 (0.0–
0.1)
-
RSV: respiratory syncytial virus, AdV: adenovirus, hMPV: human metapneumovirus, hPIV1-3: human parainfluenza virus types 1–3, CI: confidence interval
https://doi.org/10.1371/journal.pone.0180954.t002
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Fig 1. Seasonality of viral respiratory pathogens Bars indicates the total number of samples tested for each pathogen (shown on right
vertical axis). Lines indicate the proportion of positive samples for each pathogen (shown on left vertical axis). Vertical axes vary between
pathogens. Horizontal axes indicate time in monthly intervals from November 2007 through February 2014.
https://doi.org/10.1371/journal.pone.0180954.g001
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to experience a severe outcome than participants not infected with each of these pathogens
(influenza OR 0.70, 95% CI 0.60–0.81, p<0.01; RSV OR 0.82, 95% CI 0.71–0.94, p<0.01; AdV
OR 0.71, 95% CI 0.55–0.91, p<0.01; hMPV OR 0.27, 95% CI 0.18–0.41, p<0.01). Participants
with multiple infections were no more likely than participants with no infection or infection
with a single pathogen to experience severe outcomes (OR 1.23, 95% CI 0.92–1.64, p = 0.16).
When analyses were stratified by age, participants less than five years of age with an hMPV
infection were less likely than participants without an hMPV infection to experience a severe
outcome (OR 0.33, 95% CI 0.18–0.60, p<0.01), but participants with a coinfection were at
greater risk of a severe outcome than participants with no infection or infection with a single
pathogen (OR 1.60, 95% CI 1.15–2.24, p = 0.01). Among participants aged five years and older,
those with an influenza, AdV or hMPV were less likely to experience a severe outcome than
those not infected with each of these viruses (influenza OR 0.62, 95% CI 0.52–0.74, p<0.01;
AdV OR 0.42, 95% CI 0.22–0.79, p<0.01; hMPV OR 0.27, 95% CI 0.15–0.48, p<0.01).
Logistic regression was used to further examine associations with severe outcomes in par-
ticipants for whom testing for the full panel of viral respiratory viruses was performed and for
whom data on additional demographics and clinical risk factors variables are complete. In uni-
variate logistic regression examining associations between severe outcomes and viral respira-
tory pathogens, demographics and clinical risk factors, participants with hMPV infection and
participants less than five years of age were less likely to experience a severe outcome than par-
ticipants not infected with hMPV (OR 0.30, 95% CI 0.16–0.58, p<0.01) and participants aged
five years and older (OR 0.45, 95% CI 0.39–0.53, p<0.01), respectively (Table 4). Participants
Fig 2. Proportion of positive samples for each viral respiratory pathogen by month. Proportion of positive samples out of total samples tested for
each pathogen are shown.
https://doi.org/10.1371/journal.pone.0180954.g002
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Table 4. Univariate and multivariate logistic regression examining predictors of severe outcomes. Includes only individuals for whom testing for the
full panel of viral respiratory viruses was performed and for whom data on demographics and clinical risk factors are complete. Severe outcome is defined as
illness requiring ventilation or intensive care or resulting in death.
UNIVARIATE ANALYSIS
OR (95% CI) p-value
Influenza Positive 1.47 (0.91–2.39) 0.12
Negative ref.
RSV Positive 0.81 (0.64–1.04) 0.10
Negative ref.
AdV Positive 0.87 (0.67–1.13) 0.30
Negative ref.
hMPV Positive 0.30 (0.16–0.58) <0.01
Negative ref.
hPIV1 Positive 1.04 (0.49–2.23) 0.92
Negative ref.
hPIV2 Positive 1.12 (0.38–3.29) 0.84
Negative ref.
hPIV3 Positive 1.21 (0.77–1.91) 0.41
Negative ref.
Age < 5 years 0.45 (0.39–0.53) <0.01
 5 years ref.
Sex Male ref.
Female 1.11 (0.95–1.29) 0.20
Pre-existing chronic disease None ref.
Any 2.57 (2.20-3.01) <0.01
Care-seeking delay < 7 days ref.
 7 days 1.25 (1.06–1.47) 0.01
MULTIVARIATE ANALYSIS
OR (95% CI) p-value
Influenza Positive 1.18 (0.86–1.61) 0.30
Negative ref.
RSV Positive 0.87 (0.70–1.08) 0.21
Negative ref.
AdV Positive 1.22 (0.92–1.61) 0.17
Negative ref.
hMPV Positive 0.29 (0.18–0.47) <0.01
Negative ref.
hPIV1 Positive 0.97 (0.46–2.02) 0.93
Negative ref.
hPIV2 Positive 0.97 (0.34–2.60) 0.94
Negative ref.
hPIV3 Positive 1.04 (0.68–1.59) 0.96
Negative ref.
Age < 5 years 0.53 (0.44–0.62) <0.01
 5 years ref.
Pre-existing chronic disease None ref.
Any 2.34 (1.99–2.76) <0.01
Care-seeking delay None ref.
Any 1.05 (0.88–1.25) 0.59
RSV: respiratory syncytial virus, AdV: adenovirus, hMPV: human metapneumovirus, hPIV1-3: human parainfluenza virus types 1–3, OR: odds ratio, CI:
confidence interval, ref.: reference group in analysis
https://doi.org/10.1371/journal.pone.0180954.t004
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with any reported pre-existing chronic disease and participants with reported care-seeking
delay of at least seven days were at greater risk of severe outcome than participants with no
reported pre-existing chronic disease (OR 2.57, 95% CI 2.20–3.01, p<0.01) and participants
with reported care-seeking delay less than seven days (OR 1.25, 95% CI 1.06–1.47, p = 0.01).
Logistic regression was also performed separately for participants less than five years of age
and those at least five years of age (Table 5). In univariate analysis among participants less than
five years of age, participants with hMPV infection were less likely to experience a severe out-
come than participants not infected with hMPV (OR 0.30, 95% CI 0.16–1.86, p<0.01). In this
age group, participants with AdV infection, participants less than one year of age, participants
with any reported pre-existing chronic disease were more likely to experience a severe outcome
than participants not infected with AdV (1.39, 95% CI 1.03–1.86, p = 0.03), participants aged
1–4 years (OR 1.41, 95% CI 1.10–1.80, p<0.01) and participants with no reported pre-existing
chronic disease (OR 1.66, 95% CI 1.33–2.07, p<0.01), respectively. These associations remained,
and with similar odds ratios, in multivariate regression adjusting for potential confounding.
In univariate analysis among participants aged five and older, AdV and hMPV infection
were each associated with lower risk of severe outcome, compared to participants not infected
with AdV (OR 0.40, 95% CI 0.19–0.85, p = 0.02) and participants not infected with hMPV
(OR 0.30, 95% CI 0.16–0.59, p<0.01), respectively. Within this age group, age greater than 50
years and any reported pre-existing chronic disease were associated with increased risk of
severe outcome, compared with participants aged 5–49 years (2.73, 95% CI 2.17–3.42, p<0.01)
and participants with no reported pre-existing chronic disease (OR 3.43, 95% CI 2.70–4.37,
p<0.01), respectively. In multivariate logistic regression among participants aged five and
older, there remained strong evidence that hMPV infection was associated with lower risk of
severe outcome, with a similar odds ratio as in univariate analysis. There also remained strong
evidence of an association between severe outcome and age greater than 50 years (OR 2.00,
95% CI 1.57–2.55, p<0.01) or reported pre-existing chronic disease (OR 2.74, 95% CI 2.12–
3.53, p<0.01), but with lower odds ratios than in univariate analyses, reflecting an association
between increased age and reported pre-existing chronic disease.
Discussion
Results from seven years of SARI surveillance at hospitals in five countries in the Eastern Med-
iterranean Region provide important insight into the etiology, seasonality and severity of viral
respiratory pathogens among hospitalized patients in this region. Influenza, RSV and AdV
were the most common pathogens identified among SARI patients tested for viral respiratory
pathogens, although levels of infection varied across countries and over years of surveillance.
All pathogens examined were more frequently identified in participants less than five years of
age than in older participants. Monthly variation, indicating seasonal differences in levels of
infection, was observed for all pathogens. Participants with hMPV infections and participants
less than five years of age were significantly less likely than participants not infected with
hMPV and those older than five years of age, respectively, to experience a severe outcome,
while participants with a pre-existing chronic disease were at increased risk of a severe out-
come, compared to those with no reported pre-existing chronic disease.
SARI cases under the age of five tested for viral respiratory pathogens were significantly
more likely than older patients to be infected with each of the pathogens examined, except
influenza. This is not unexpected since these pathogens have a strong association with this age
group, while influenza is associated with a higher risk of hospitalization in the older age groups
[20]. Nearly 80% of children are exposed to RSV by age two, 100% to hMPV by age five and
90% to hPIV by age five [8]. hPIV are a significant etiology of LRTI in children [21], second
Viral SARI in EMR
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Table 5. Univariate and multivariate logistic regression examining predictors of severe outcomes by age. Includes only individuals for whom testing
for the full panel of viral respiratory pathogens was performed and for whom data on predictor variables are complete. Severe outcome is defined as illness
requiring ventilation or intensive care or resulting in death. Participants are divided into age less than five years and age five years or older.
UNIVARIATE ANALYSIS
AGE < 5 YEARS AGE  5 YEARS
OR (95% CI) p-value OR (95% CI) p-value
Influenza Positive 1.47 (0.91–2.39) 0.12 0.92 (0.63–1.35) 0.67
Negative ref. ref.
RSV Positive 0.81 (0.64–1.04) 0.10 0.75 (0.49–1.14) 0.17
Negative ref. ref.
AdV Positive 1.39 (1.03–1.86) 0.03 0.40 (0.19–0.85) 0.02
Negative ref. ref.
hMPV Positive 0.30 (0.16–0.58) <0.01 0.30 (0.16–0.59) <0.01
Negative ref. ref.
hPIV1 Positive 1.04 (0.49–2.23) 0.92 0.63 (0.70–5.64) 0.68
Negative ref. ref.
hPIV2 Positive 1.12 (0.38–3.29) 0.84 0.63 (0.70–5.64) 0.68
Negative ref. ref.
hPIV3 Positive 1.21 (0.77–1.91) 0.41 1.08 (0.41–2.83) 0.87
Negative ref. ref.
Age < 1 year 1.41 (1.10–1.80) <0.01 n/a
1–4 years ref. n/a
5–49 years n/a ref.
 50 years n/a 2.73 (2.17–3.42) <0.01
Sex Male ref. ref.
Female 1.00 (0.80–1.26) 0.98 1.17 (0.94–1.46) 0.16
Pre-existing chronic disease None ref. ref.
Any 1.66 (1.33–2.07) <0.01 3.43 (2.70–4.37) <0.01
Care-seeking delay < 7 days ref. ref.
 7 days 1.15 (0.90–1.48) 0.26 1.16 (0.92–1.46) 0.22
MULTIVARIATE ANALYSIS
AGE < 5 YEARS AGE  5 YEARS
OR (95% CI) p-value OR (95% CI) p-value
Influenza Positive 1.63 (0.98–2.67) 0.05 0.97 (0.65–1.46) 0.89
Negative ref. ref.
RSV Positive 0.82 (0.63–1.06) 0.12 0.89 (0.57–1.39) 0.59
Negative ref. ref.
AdV Positive 1.48 (1.09–2.00) 0.01 0.57 (0.26–1.25) 0.16
Negative ref. ref.
hMPV Positive 0.31 (0.16–0.59) <0.01 0.29 (0.15–0.58) <0.01
Negative ref. ref.
hPIV1 Positive 1.04 (0.48–2.25) 0.92 0.93 (0.10–8.74) 0.95
Negative ref. ref.
hPIV2 Positive 1.14 (0.38–3.41) 0.81 0.66 (0.07–6.37) 0.72
Negative ref. ref.
hPIV3 Positive 1.04 (0.65–1.66) 0.87 1.33 (0.49–3.66) 0.58
Negative ref. ref.
Age < 1 year 1.43 (1.11–1.83) <0.01 n/a
1–4 years ref. n/a
5–49 years n/a ref.
 50 years n/a 2.00 (1.57–2.55) <0.01
Pre-existing chronic disease None ref. ref.
Any 1.69 (1.34–2.12) <0.01 2.74 (2.12–3.53) <0.01
RSV: respiratory syncytial virus, AdV: adenovirus, hMPV: human metapneumovirus, hPIV1-3: human parainfluenza virus types 1–3, OR: odds ratio, CI:
confidence interval, ref.: reference group in analysis, n/a: not applicable
https://doi.org/10.1371/journal.pone.0180954.t005
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only to RSV [11], and AdV are the second most common viral pathogen in children under two
years of age [22].
Hospitalized patients with influenza infection have been described in detail in Egypt [23],
Jordan [24] and Oman [25]. However, previous studies of other respiratory infections in the
region have focused primarily on pediatric cases less than five years of age. Within this age
group, the prevalence of RSV in our study population was higher than previous studies of out-
patients in Egypt [26, 27] and Oman [28], suggesting possible increased severity for RSV infec-
tions, but lower than that identified in studies of hospitalized patients in Jordan conducted in
winter when prevalence is expected to be highest [29, 30] and higher than a smaller study in
Upper Egypt [31]. AdV and hMPV were found at levels comparable to previous studies of
both outpatient and inpatient populations [22, 26, 28, 31]. Studies of hPIV are more difficult to
compare since some studies have not specified virus types, but overall prevalence in the cur-
rent study appears to be similar to previous studies in Egypt [26] and Oman [28].
The seasonality of the viral respiratory pathogens examined in this study generally followed
that which has been documented in temperate climates. As in temperate climates, influenza was
most common in winter months between October and February [32]. RSV showed circulation
throughout most of the year but was highly seasonal, with annual peaks between November and
February. This finding is consistent with both temperate North America [8] and with previous
studies that have identified RSV seasons in Egypt, Jordan, Qatar, Saudi Arabia and the United
Arab Emirates within the same time frame [33] and with the highest peak in January [30]. The
height of hMPV circulation was between January and May, which is consistent with its pattern
of infection in temperate climates, where peaks occur either with or just after RSV in late winter
or spring [7]. For AdV, peaks were noted between April and July, which is comparable to circu-
lation patterns in temperate climates where the virus is seen throughout the year with outbreaks
in late winter, spring or early summer [8]. The seasonality of hPIV1 was similar to, though ear-
lier than, virus circulation patterns in the United States [10], and variations in hPIV2 infection
were consistent with patterns noted in the United States [10, 11]. hPIV3 follows an annual pat-
tern in the United States, with annual peaks between April and June [10]; a pattern was also
noted in the EMR with peaks between May and August in most years.
Although PCR has been established as a valid diagnostic assay with high sensitivity and
specificity for respiratory viruses examined in this study [8, 34], the clinical implications of
positive laboratory results are less straightforward. The relationship between RSV infection
and clinical disease has been established, as infections among asymptomatic individuals are
rare [35, 36]. AdV infection levels in asymptomatic children and adults vary [35, 37, 38],
though this may be attributable to differences in sampling methodology since throat swabs
may detect latent AdV DNA in tonsil tissue [35]. Studies suggest that asymptomatic infection
with hMPV is rare among children [39–41], but results from adult populations are less defini-
tive, with reports of varying levels of infection among asymptomatic individuals [36, 42, 43].
Even fewer data are available on hPIV infection in asymptomatic individuals, so the clinical
impact of hPIV infection is unclear.
The clinical implications of positive laboratory results are further complicated by co-infec-
tions. Multiple viral respiratory pathogens were identified in 501/9,316 (5.4%) samples for
which testing for the full panel of viral respiratory pathogens, as well as influenza, was per-
formed. Co-infection with two or more viral respiratory pathogens is common and has been
noted in previous studies of viral respiratory infections among pediatric populations in the
region [26, 29, 44]. Multiple infections complicate diagnosis because the relative clinical
impact of each pathogen is unclear [45], and certain pathogens, such as AdV, the most com-
mon co-infecting pathogen identified in this study, are routinely found in the upper airways
[46]. There are suggestions that co-infections may increase severity of disease [8, 9], but this
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conclusion has not been found consistently [4, 46]. The observed impact of co-infections on
disease severity may be affected by variations in virus circulation or study methodology [9],
and so further studies with consistent testing for a full panel of pathogens are needed to vali-
date the impact of multiple viral respiratory infections on clinical outcomes.
In analyses to assess associations with severe outcomes in this study, there was strong evi-
dence that individuals with SARI and hMPV infection were less likely to experience a severe
outcome than individuals with SARI not infected with hMPV, after controlling for age and
pre-existing chronic disease. Among participants aged less than five years, there was strong
evidence that those with AdV infection were more likely to experience a severe outcome than
participants not infected with AdV in this age group. There was also some evidence that influ-
enza infection may be associated with a severe outcome in participants less than five years of
age, but a larger study is needed to fully assess this association and associations between other
viral respiratory pathogens and severe outcomes. In these analyses, pre-existing chronic dis-
ease was the strongest predictor of a severe outcome among participants in this study. Because
of associations between chronic disease and age, older participants in this study were at greater
risk of severe outcomes, despite low levels of infection with pathogens of interest.
There are several limitations to the current study. Not all enrolled SARI cases were sampled
and tested for all viral respiratory pathogens throughout the course of surveillance for a variety of
reasons including patient refusal at the time of sample collection, limited sample quantity following
influenza testing, problems with sample transport and occasional interruptions in the availability
of necessary supplies. Therefore results are limited to a subset of the full spectrum of hospitalized
patients with severe respiratory infections and cannot be used for burden estimates. Additionally,
samples were collected through routine surveillance activities rather than through random sam-
pling, which further limits the applicability of findings. Because testing focused on a limited panel
of viral respiratory pathogens, other viral and bacterial etiologies which may have been factors in
co-infections or severity of disease were excluded. The incorporation of testing for additional path-
ogens or testing for the same pathogens among outpatients or in an asymptomatic control popula-
tion in the region would offer an opportunity to address some of the challenges of interpreting
results from this study. Furthermore, despite monitoring efforts, data completeness, as noted in
various denominators in the tables, limited data analyses and affected confidence intervals.
Despite these limitations, the current study provides a substantial amount of information
the viral etiology, seasonality and severity of respiratory infections among hospitalized SARI
patients in the Eastern Mediterranean Region. As SARI surveillance continues and expands
through the EMARIS network, it is important to maintain and improve surveillance for viral
respiratory pathogens in order to monitor changes in the etiology, severity and seasonality of
pathogens of interest.
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